Funding Opportunity PAR-23-132 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support research that addresses research questions relevant to human dental, oral, or craniofacial (DOC) diseases and conditions through analysis of existing and publicly available genomics data using data science approaches.

Funding Opportunity PAR-23-133 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support research that addresses research questions relevant to human dental, oral, or craniofacial (DOC) diseases and conditions through analysis of existing and publicly available genomics data using data science approaches.

Funding Opportunity RFA-AI-23-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research focused on the development of convenient small animal models that will support infection and replication of HBV and/or HCV, ideally leading to the dichotomous outcomes of clearance and persistence. Alternatively, closely related surrogate virus-host systems or robust xenotransplantation models dually engrafted with human liver cells and human immune systems can be developed.

Funding Opportunity RFA-RM-23-007 from the NIH Guide for Grants and Contracts. The NIH Director's Early Independence Award supports rigorous and promising junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations, are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

Funding Opportunity RFA-MH-23-260 from the NIH Guide for Grants and Contracts. This NIMH RFA concept seeks applications proposing experimental and non-experimental research that evaluates multilevel preventive strategies to reduce suicide risk (suicide ideation and behavior, including acts of self-harm/suicide) and promote resilience across the life span in low-and middle-income countries (LMICs). Globally, there is a critical need to implement culturally adapted multilevel preventive approaches at the individual (selective prevention) and population level (universal prevention) for people across the lifespan in LMICs, focusing on multiple risks and protective factors.

Notice NOT-HD-23-008 from the NIH Guide for Grants and Contracts

Notice NOT-DC-23-006 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-055 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-054 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-23-022 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory and innovative research applications focused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this NOFO.

Funding Opportunity RFA-NS-23-021 from the NIH Guide for Grants and Contracts. The purpose of thisNotice of Funding Opportunity (NOFO)is to invite applicationsfocused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this NOFO.

Funding Opportunity RFA-RM-23-005 from the NIH Guide for Grants and Contracts. The NIH Directors New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important problems relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Directors New Innovator Award Program is a component of the High-Risk, High-Reward Research Program of the NIH Common Fund.

Notice NOT-AI-23-040 from the NIH Guide for Grants and Contracts

Notice NOT-AT-24-003 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-23-006 from the NIH Guide for Grants and Contracts. The NIH Directors Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nations research workforce. Individuals from diverse backgrounds, including those from underrepresented groups (see, Notice of NIH's Interest in Diversity, NOT-OD-20-031) are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications are welcome from the full spectrum of eligible institutions in all geographic locations and in all topic areas relevant to the broad mission of NIH, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. Towards the objective of funding the best possible science, the Office of Strategic Coordination and the Center for Scientific Review are piloting a process for initial peer review of applications received in response to this FOA in which the identity of the investigators and institutions are withheld until the last phase of review. Instructions for anonymizing components of the application are given in Section IV and must be carefully followed. A description of the review process is given in Section V.

Notice NOT-AT-24-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-105 from the NIH Guide for Grants and Contracts

Notice NOT-DC-23-005 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-078 from the NIH Guide for Grants and Contracts

Notice NOT-HG-23-023 from the NIH Guide for Grants and Contracts